Royalty Pharma PLC (RPRX) Actualités

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty Pharma Announces R&D Funding Collaboration With Biogen

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has...

Form 8-K - Current report

Royalty Pharma Reports Q4 and Full Year 2024 Results

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and...

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 425 - Prospectuses and communications, business combinations